SINTX ANNOUNCES 30-YEAR SPINE FUSION DATA WITH SILICON NITRIDE IMPLANTS
January 03 2019 - 9:00AM
SINTX Technologies (NASDAQ: SINT) today reported the independent
publication of 30-year clinical outcomes of lumbar fusion
surgeries, performed with silicon nitride implants. The paper
titled “Anterior Lumbar Interbody Fusion Using Reaction Bonded
Silicon Nitride Implants” appeared in the December 2018 edition of
the World Neurosurgery journal, and the findings were also featured
at the 2018 Annual Scientific Meeting of the Neurosurgical Society
of Australasia.
Dr. Ralph Mobbs from the University of New South
Wales, Sydney, authored the study. Dr. Mobbs stated: “This work is
of historical significance, being the first clinical study of
silicon nitride as an implant material, the first commercial
anterior lumbar interbody fusion with a synthetic material, the
first design of a spinal interbody implant with endplate porosity
to promote fusion, and the longest clinical follow-up of any
implant material in spine surgery. This report clearly establishes
the place of silicon nitride in the annals of spine surgery,” said
Professor Mobbs.
“This work reflects the only known use of
silicon nitride implants, outside the spine products manufactured
by our company,” said Dr. Sonny Bal, Chairman of SINTX
Technologies. “Despite a much earlier material composition and
implant design, silicon nitride proved itself even three decades
after spinal implantation. These findings are entirely consistent
with the more modern data published by us, showing earlier fusion,
excellent biocompatibility, ease of radiographic imaging, and other
advantages of our silicon nitride spine implants. The SINTX
formulation of silicon nitride is enhanced and improved even
further with sintering agents that accelerate bioactivity and
confer antibacterial advantages.”
“This paper is a compelling affirmation of our
full confidence in silicon nitride as the ideal spine biomaterial
platform, whether as an implant, surface coating, or composite
formulation with other biomaterials. This report will support our
sales objectives, as we prepare an official launch in the coming
months in Australia - the first place to use silicon nitride in
spinal fusion surgery,” said Daniel Chon, CEO of Dallas-based
CTL-Amedica, the exclusive retail channel for silicon nitride
spinal implants made by SINTX Technologies.
About SINTX Technologies
SINTX Technologies is an innovative biomaterials
and OEM company that develops and commercializes silicon nitride
for various biomedical applications including orthopedic, dental
and arthroplasty.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (“PSLRA”) that are subject to a number of risks
and uncertainties. Readers are cautioned not to place undue
reliance on the forward-looking statements, which speak only as of
the date on which they are made and reflect management’s current
estimates, projections, expectations and beliefs. A discussion of
those risks and uncertainties can be found in Sintx's Risk Factors
disclosure in its Annual Report on Form 10-K, filed with the
Securities and Exchange Commission (SEC) on March 29, 2018, and in
Sintx's other filings with the SEC. SINTX disclaims any obligation
to update any forward-looking statements. Sintx undertakes no
obligation to publicly revise or update the forward-looking
statements to reflect events or circumstances that arise after the
date of this report.
Contacts: SINTX Technologies 801-839-3502 IR@sintx.com
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Sep 2024 to Oct 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Oct 2023 to Oct 2024